DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

NEWS RELEASE

Released: December 23, 2008

Department of Defense Prostate Cancer Research Program
Funding Opportunities for Fiscal Year 2009

The Fiscal Year 2009 (FY09) Defense Appropriations Act provides $80 million to the Department of Defense Prostate Cancer Research Program (PCRP) to support innovative, high impact prostate cancer research. This program is administered by the US Army Medical Research and Materiel Command through the Office of the Congressionally Directed Medical Research Programs (CDMRP).

FY09 PCRP program announcements and application instructions for the following award mechanisms are anticipated to be posted on Grants.gov in January-February 2009.

Award Mechanism Eligibility Key Mechanism Elements Funding
Idea Development Award Independent investigator at or above the level of Assistant Professor (or equivalent)
  • Supports innovative approaches to prostate cancer research that may include high risk, provided there is potential for significant impact
  • Emphasis is on innovation and impact
  • Preliminary data are encouraged but not required
  • NEW: Applications must address one or more of the FY09 Focus Areas: Imaging, Biomarkers, Therapy, Genetics, Tumor Biology, and Survivorship
  • NEW: Preproposal is required; application submission is by invitation only
  • Clinical trials are not permitted
  • Maximum funding of $450K for direct costs (plus indirect costs)
  • Period of performance cannot exceed 3 years
Population-Based Idea Development Award (NEW!) Independent investigator at or above the level of Assistant Professor (or equivalent)
  • Supports innovative, high-impact approaches to prostate cancer research that can be achieved from the perspective of population-based studies; approaches may include high risk, provided there is potential for significant impact
  • Emphasis is on innovation and impact
  • Areas of population-based studies include but are not limited to population genomics, meta-analysis, prospective and/or retrospective analyses, diet and exercise, survival, population surveillance with specific relevance to prostate cancer
  • Preliminary data are encouraged but not required
  • Clinical trials are not permitted
  • Maximum funding of $600K for direct costs (plus indirect costs)
  • Period of performance cannot exceed 4 years
Synergistic Idea Development Award Investigators at or above the level of Assistant Professor (or equivalent)
  • Supports new or existing partnerships between two or three independent investigators to address a central innovative question in prostate cancer that may include high risk, provided there is a potential for significant impact
  • Emphasis is on synergy, innovation, and impact
  • Preliminary data are encouraged but not required
  • NEW: Applications must address one or more of the FY09 Focus Areas: Imaging, Biomarkers, Therapy, Genetics, Tumor Biology, and Survivorship
  • NEW: Preproposal is required; application submission is by invitation only
  • Clinical trials are not permitted
  • Maximum funding of $750K for direct costs (plus indirect costs)
  • Period of performance cannot exceed 3 years
New Investigator Award Independent investigators with institutional support who, at the time of submission:
  • Are within 3 years of first independent faculty position;and
  • Have sufficient skills and knowledge to function independently without mentorship;and
  • Can provide evidence of institutional support such as start-up funds, space, resources, etc.
  • Supports early-career investigators with innovative, high-impact ideas or new technologies relevant to prostate cancer
  • PIs must name a Collaborator with a proven record in prostate cancer research
  • Emphasis is on PI and Collaborator, innovation, and impact
  • Preliminary data are not required
  • NEW: Applications must address one or more of the FY09 Focus Areas: Imaging, Biomarkers, Therapy, Genetics, Tumor Biology, and Survivorship
  • Clinical trials are not permitted
  • Maximum funding of $225K for direct costs (plus indirect costs)
  • Period of performance cannot exceed 3 years
Prostate Cancer Pathology Resource Network (NEW!) Independent investigators at or above the level of Assistant Professor (or equivalent)
  • Supports the development of a consortium infrastructure that will facilitate prostate cancer research through the collection, processing, annotation, storage, and distribution of human biospecimens in a collaborative fashion across multiple institutions
  • Each proposal must include one Coordinating Center and two Pathology Resource Sites to be jointly responsible for development of the biospecimen repository for prostate cancer research
  • Sites must provide plans for biospecimen collection, processing, annotation, storage, distribution, quality assurance, bioinformatics and data management, ethical and regulatory issues, and plans for acquiring samples from populations disproportionately affected by prostate cancer
  • Encourages submissions from investigators with enhanced skills in human biospecimen procurement, human tissue repositories, distribution, and working within a collaborative consortium-type network of multiple institutions
  • Consortium is expected to provide a plan to achieve financial self-sufficiency such that operations can continue after the award ends
  • Maximum funding of $2.5M for direct costs (plus indirect costs)
  • Period of performance cannot exceed 3 years
  • Funds may not be used for laboratory or clinical research
Health Disparity Research Award PIs may apply for only one of the following categories:

Transitioning Investigators:
Must hold Ph.D. and/or M.D.; and
  • Must have received no more than $300,000 in direct costs in aggregate as a PI or co-PI of a federally or privately funded, non-mentored peer-reviewed grant; and
  • At the time of proposal submission, must either:
    • Have documentation of receipt of their first independent faculty appointment (or equivalent); or
    • Be within 3 years of having started their first independent faculty position (or equivalent)
Early-Career Investigators:
Independent investigators who are, at the time of proposal submission:
  • Within 3 years of first independent faculty position; and
  • Have sufficient skills and knowledge to function independently without mentorship; and
  • Can provide evidence of institutional support such as start-up funds, space, resources, etc.
Established Investigator PIs:
Independent investigator at or above the level of Assistant Professor (or equivalent)
  • Supports prostate cancer health disparity-focused projects by investigators at multiple points in their careers
  • PI or collaborator(s) should have a connection to, or effectiveness in working with, an affected population or community
  • For Transitioning and Early-Career Investigators, institution must provide 50% protection of PI's time for research
  • Designatedmentor with experience in prostate cancer health disparity research required for Transitioning Investigator Awards
  • Collaborator with experience in prostate cancer health disparity research required for Early-Career Investigator Awards
  • NEW: Applications must address one or more of the FY09 Focus Areas: Imaging, Biomarkers, Therapy, Genetics, Tumor Biology, and Survivorship
  • Transitioning Investigators: Maximum funding of $225K for direct costs (plus indirect costs)
  • Early-Career Investigators: Maximum funding of $225K for direct costs (plus indirect costs)
  • Established Investigators: Maximum funding of $450K for direct costs (plus indirect costs)
  • Period of performance cannot exceed 3 years for all three categories
Health Disparity Training Award Predoctoral Ph.D. and M.D./Ph.D. PIs:
  • Must be enrolled full-time in an accredited doctoral program and must have completed all predissertation requirements by October 1, 2009
Postdoctoral Ph.D. PIs:
  • Must have successfully defended a doctoral thesis by October 1, 2009; and
  • Have 3 years or less of postdoctoral fellowship experience by October 1, 2009
Postdoctoral M.D. PIs:
  • Must have an M.D.; and
  • Must be able to devote at least 40% effort; and
  • By August 1, 2009, must be:
    • Enrolled in an accredited intern, residency, or fellowship training program, or
    • Within 3 years of the last formal training
  • Supports training in prostate cancer disparity research for individuals in the early stages of their careers
  • PIs must have a designated mentor who is an experienced prostate cancer health disparity researcher
  • PI or mentor must demonstrate a connection to, or effectiveness in working with, the affected population or community
  • Emphasis is on PI, mentor, and training program and environment
Predoctoral Ph.D. and M.D./Ph.D. PIs:
  • Maximum funding of $92.5K for direct costs (plus 8% indirect costs)
  • Period of performance cannot exceed 3 years
Postdoctoral Ph.D. PIs:
  • Maximum of $115K for direct costs (plus 8% indirect costs)
  • Period of performance cannot exceed 2 years
Postdoctoral Ph.D. PIs:
  • Maximum of $60K per year for direct costs (plus 8% indirect costs)
  • Period of performance cannot exceed 2 years
Collaborative Undergraduate Historically Black Colleges and Universities (HBCU) Student Summer Training Program Award Independent investigators at or above the level of Assistant Professor (or equivalent) with a proven record in prostate cancer research and training
  • Supports new or existing summer prostate cancer training programs for undergraduate HBCU students at host institutions
  • Must enroll a minimum of four undergraduate HBCU trainees per year
  • Host institution must have a record of achievement in prostate cancer research and training
  • Maximum funding of $185K for direct costs (plus 8% indirect costs)
  • Period of performance cannot exceed 3 years
Physician Research Training Award At the time of proposal submission, the PI must be either:
  • A physician with clinical duties and/or responsibilities in the last year of an accredited medical residency or medical fellowship program; or
  • A physician within 3 years of first independent faculty appointment
  • Supports training of physicians with clinical duties for careers in prostate cancer research
  • PIs must have a mentor with an established research program in prostate cancer
  • Emphasis is on PI, mentor, and training program and environment
  • Institution must provide at least 40% protection of PI's time for research
  • Emphasis is on PI, mentor, and training program and environment
  • NEW FOR FY09 Applications must address one or more of the FY09 Focus Areas: Imaging, Biomarkers, Therapy, Genetics, Tumor Biology, and Survivorship
  • Maximum funding of $130K for direct costs per year (plus 8% indirect costs)
  • Period of performance is 3 years minimum and 5 years maximum
Prostate Cancer Training Award Predoctoral Ph.D. and M.D./Ph.D. PIs:
  • Must be enrolled full-time in an accredited doctoral program and must have completed all predissertation requirements by October 1, 2009
Postdoctoral Ph.D. PIs:
  • Must have successfully defended a doctoral thesis by October 1, 2009; and
  • Have 3 years or less of postdoctoral fellowship experience by October 1, 2009
Postdoctoral M.D. PIs:
  • Must have an M.D.; and
  • Must be able to devote at least 40% effort; and
  • By August 1, 2009, must be:
    • Enrolled in an accredited intern, residency, or fellowship training program, or
    • Within 3 years of the last formal training
  • Supports prostate cancer research training for individuals in the early stages of their careers
  • All PIs must have a designated mentor
  • Emphasis is on PI, mentor, and training program and environment
Predoctoral Ph.D. and M.D./Ph.D. PIs:
  • Maximum funding of $92.5K for direct costs (plus 8% indirect costs)
  • Period of performance cannot exceed 3 years
Postdoctoral Ph.D. PIs:
  • Maximum of $115K for direct costs (plus 8% indirect costs)
  • Period of performance cannot exceed 2 years
Postdoctoral Ph.D. PIs:
  • Maximum of $60K per year for direct costs (plus 8% indirect costs)
  • Period of performance cannot exceed 2 years

Information in this pre-announcement is being provided to allow investigators time to plan and develop applications. The government reserves the right to make changes to the award mechanisms offered and the mechanism elements, if necessary. All applications must conform to the final program announcements, which will be available for electronic downloading from the Grants.gov website in January-February 2009. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

A pre-application (i.e., pre-proposal or letter of intent, depending on the award mechanism) is required for all award mechanisms and must be submitted through the CDMRP eReceipt website (http://cdmrp.org) prior to application submission. Applications must be submitted through the federal government's single-entry portal, Grants.gov. Requests for email notification of the program announcements release may be sent to help@cdmrp.org. For more information about the PCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact: